The Macular Degeneration and Diabetes Center of Florida Eye Institute offers the latest FDA approved Beovu injection for patients with wet macular degeneration.
Wet AMD is the leading cause of severe vision loss and legal blindness for people over the age of 65. It’s estimated 1.75 million people in the U.S. will be living with wet AMD in 2020.
Beovu was approved October 8, 2019 by the Food and Drug Administration and is the newest option to treat the potentially blinding effects of wet macular degeneration affecting nearly 1.75 million Americans over the age of sixty.
In clinical trials, patients achieved greater visual gains and fluid reduction with quarterly dosing schedules of Beovu compared to other medications with 4-6-week injection timetables.
“I am excited about this latest advance to treat patients with macular degeneration” says Dr. Thomas Baudo, fellowship trained retina physician and surgeon with Florida Eye Institute in Vero Beach, FL.
“Beovu was engineered to deliver a higher concentration of drug binding agents, suppressing the growth of abnormal blood vessels that leak excess fluid into the retina and cause visual distortion. It’s the first FDA approved medication to offer less frequent dosing in the first year while maintaining clinical effectiveness. Beovu adds to our arsenal of customized treatment options for improved outcomes.”
Age-related macular degeneration is a disease of the macula, the part of the eye responsible for central vision. It can interfere with the ability to read, drive, and see the faces of loved ones. In the wet form of the disease, abnormal blood vessels grow and leak fluid into the macula, causing vision loss.
Early symptoms of macular degeneration include wavy distortions or blank spots in the center of vision. As the disease progresses, patients lose the ability to see objects directly in front of them resulting in a loss of independence, making it a growing public health concern.
Thomas Baudo, MD, Board Certified Ophthalmologist, trained at Thomas Jefferson University followed by a retina fellowship at the renowned National Retina Institute in Baltimore, Maryland. He joined Florida Eye Institute in 2001 and dedicates his practice to the exclusive treatment of macular degeneration, diabetic eye disease, and retinal surgery.